Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Conditions: Diabetes type1; Obesity
Interventions: Drug: Semaglutide Pen Injector; Drug: Placebo
Sponsors: Yale University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Novo Nordisk A/S
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 14, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments